Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer Who Have Experienced Disease Progression During Platinum-based Chemotherapy

NCT00556322 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00556322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00556322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer Who Have Experienced Disease Progression During Platinum-based Chemotherapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2012
Enrollment
424 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer